
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KAD101
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Northway Biotechpharma
Deal Size : Undisclosed
Deal Type : Agreement
Northway Biotech, Kaida BioPharma Ink Manufacturing Deal for KAD101 Oncology Drug
Details : Under the agreement, Northway will initiate the production of Kaida's lead product candidate, KAD101, which is being evaluated for the treatment of ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : KAD101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Northway Biotechpharma
Deal Size : Undisclosed
Deal Type : Agreement
